1. Examining Hemodialysis Reliable Outflow catheter performance and cost in hemodialysis access.
- Author
-
Torrent DJ, Maness MR, Kachare SD, Zink JN, Haisch CE, Harland RC, Morgan C, Guyton RL, Colomb AG, Barham DW, Katz EC, and Stoner MC
- Subjects
- Arteriovenous Shunt, Surgical economics, Female, Graft Occlusion, Vascular economics, Graft Occlusion, Vascular mortality, Health Expenditures statistics & numerical data, Humans, Kaplan-Meier Estimate, Kidney Failure, Chronic economics, Kidney Failure, Chronic mortality, Length of Stay statistics & numerical data, Male, Middle Aged, Outcome Assessment, Health Care economics, Renal Dialysis economics, Renal Dialysis mortality, Retrospective Studies, Vascular Access Devices economics, Arteriovenous Shunt, Surgical standards, Graft Occlusion, Vascular prevention & control, Kidney Failure, Chronic therapy, Renal Dialysis instrumentation, Vascular Access Devices standards
- Abstract
Background: The Hemodialysis Reliable Outflow (HeRO) vascular access device is a hybrid polytetrafluoroethylene graft-stent construct designed to address central venous occlusive disease. Although initial experience has demonstrated excellent mid-term patency rates, subsequent studies have led to external validity questions. The purpose of this study was to examine a single center experience with this vascular access device in challenging access cases with associated costs., Methods: A retrospective study representing the authors' cumulative HeRO vascular access device experience was undertaken. The primary endpoint was graft failure or death, with secondary endpoints including secondary intervention rates and cost., Results: Forty-one patients with 15,579 HeRO days and a mean of 12.7 ± 1.5 mo with the vascular access device were available for analysis. Secondary patency was 81.6% at 6 mo and 53.7% at 12 mo. The reintervention rate was 2.84 procedures per HeRO vascular access device year. Associated HeRO costs related to subsequent procedures were estimated at $34,713.63 per patient/y., Conclusions: These data on the patency and primary outcome data diverge significantly from initial multicenter studies and represent a real-world application of this technology. It is costly to maintain patency. Use of HeRO vascular access devices should be judicious with outcome expectations reduced., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF